FINWIRES · TerminalLIVE
FINWIRES

禮來公司將以70億美元收購凱洛尼亞公司，以加強其癌症治療產品組合。

By

-- 禮來公司（LLY）已同意以最高70億美元收購臨床階段生物技術公司Kelonia Therapeutics，這家製藥巨頭希望藉此加強其癌症治療產品組合。 兩家公司週一表示，這筆交易的對價包括32.5億美元的首付款，以及在達到某些臨床、監管和商業里程碑後支付的後續款項。 此次收購將使禮來公司獲得KLN-1010，這是Kelonia公司用於治療多發性骨髓瘤（一種骨髓漿細胞癌）的主要在研藥物。該產品目前正在進行I期臨床試驗。 禮來腫瘤總裁Jacob Van Naarden表示：「KLN-1010的早期臨床數據令人鼓舞，它不僅有望成為多發性骨髓瘤患者的治療新進展，也驗證了Kelonia的研發平台。我們期待與Kelonia團隊攜手合作，加速推進KLN-1010的研發，以滿足患者的需求。」該交易將於今年完成，該交易預計將於今年完成半年需。 Kelonia 執行長 Kevin Friedman 表示：「我們已經證明，與體外（嵌合抗原受體）T 細胞療法相比，我們能夠以顯著降低的複雜性和成本實現多發性骨髓瘤的深度緩解。結合禮來的優勢，我們的體內（基因定位系統）平台有望將細胞療法的應用範圍擴展到目前血液系統惡性腫瘤的 CAR-T 療法之外。」 禮來股價週一下午交易中小幅下跌 0.1%，今年迄今的跌幅約為 14%。 上月底，禮來宣布了一項高達 78 億美元的交易，擬收購英國 Centessa Pharmaceuticals 公司，以加強其神經科學產品線並擴大睡眠醫學領域。今年早些時候，該公司同意以高達 24 億美元的價格收購專注於免疫細胞工程的生物技術公司 Orna Therapeutics。 禮來公司計劃於4月30日公佈第一季財務業績。

Price: $927.86, Change: $+0.83, Percent Change: +0.09%

Related Articles

Equities

AKITA Drilling Announcing "Transformative" Acquisition of Fox Drilling and Elimination of Dual Class Share Structure

$AKT-A.TO$AKT-B.TO
Asia

Koei Tecmo's Profit Jumps 14% in Fiscal Year 2025

Koei Tecmo's (TYO:3635) profit attributable to owners of the parent increased 14% to 42.8 billion yen for the fiscal year 2025 from 37.6 billion yen a year earlier.The amusement and video game company's earnings per share increased to 131.67 yen from 113.65 yen a year ago, according to a Tokyo bourse filing on Monday.Net sales climbed 6.3% to 88.4 billion yen for the full year ended March 31 from 83.2 billion yen in the prior year.In a separate disclosure, Koei Tecmo raised its final dividend to 66 yen per share, from 43 yen forecasted earlier, payable from June 19.For the fiscal year 2026, the company expects attributable profit of 31 billion yen, basic EPS of 95.38 yen, and net sales of 90 billion yen.Koei Tecmo plans to pay a year-end dividend of 48 yen per share for the year, which is lower than the amount paid the previous year.

$TYO:3635
Treasury

BMO on The Day, Week Ahead in Canada

The US dollar (USD) is softer (BBDXY -0.25%) with the Canadian dollar (CAD or loonie) firmer (CAD per USD -0.44%) early Monday, said Bank of Montreal (BMO).The Bank of Canada will release its policy statement on Wednesday, together with the new Monetary Policy Report (MPR). The BoC is expected to keep rates unchanged, noted the bank.The BoC will also release its latest MPR with updated estimates for potential growth -- in the low-1% range -- and the neutral rate, seen in the 2.25%-to-3.25% range, stated BMO.Also on this week's Canadian docket there is Tuesday's Spring Economic Update from the Canadian government, which will refresh the estimates published in the November FY26/27 budget. There seems to be some fiscal upside compared with the budget's original $65.4 billion deficit, pointed out the bank.On Thursday, BMO expects real gross domestic product growth to accelerate another tenth to 0.2% month over month in February, in line with Statistics Canada's flash estimate. The March flash estimate will be one to watch as it will capture the initial reaction to the outbreak of the Iran war.

$$CAD$$CXY$$USD